This is it: Brineura, Imfinzi square off in #FierceMadness final

drug names bracket FPMK
Brineura defeated Zepatier and Imfinzi decimated Trulance to reach the final matchup. (FiercePharma)

The final #FierceMadness showdown is set: BioMarin’s Brineura will face off against AstraZeneca’s Imfinzi in the drug name championship for 2018.

To get here, Brineura took out Merck’s Zepatier with a vote of 1,383-622, while Imfinzi blew out Synergy’s Trulance in the highest-scoring contest of the tournament: a whopping 3,940-932.

While big scores and blowouts in the NCAA basketball tournament mean red-hot shooting and smothering defense, insider rallies seem to be pushing the FierceMadness contest forward.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

BioMarin-ers outed themselves several rounds ago and continue their dedication to the company and drug cause with "kumbaya" rallying cries and, of course, many serious comments on Brineura and its effects. As one person wrote, “Because every childhood disease deserves a cure, and this is a step toward that cure.”

Zepatier voters still tried, however, as one joked, “This is pretty much a referendum on BioMarin's PR by now. I feel like one of the Spartans from 300 for this—I know I have no chance of stopping the horde, but dammit I'm going to die fighting.”

It’s harder to pinpoint the cause of the Imfinizi surge, as most voters did vote in both contests and none mentioned AZ or Imfinzi as employer or brand work. However, there has been a definite surge of support for the drug since its last round of voting, where it only garnered 287 total votes and won by a narrow two-point margin.

Championship voting begins now and will continue through Tuesday night at 10 p.m. ET. It’s a short round and it’s for all the marbles, so get out the vote. We’ll be back with the winner on Wednesday.


Championship (Vote here)

(10) Brineura vs. (5) Imfinzi

Maker: BioMarin.
Indication: CLN2 disease.
Sounds like: a saltwater shrimp species.

Maker: AstraZeneca.
Indication: unresectable Stage III non-small cell lung cancer and bladder cancer.
Sounds like: when something will never, ever, ever happen again.

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.